New guidelines from the American Thyroid Association (ATA) that will impact patient care are due to be published, including guidance on managing thyroid disorders—such as hypothyroidism—during pregnancy. These eagerly awaited guidelines will change some aspects of patient care, including a likely update on who to screen for thyroid dysfunction (changes to those deemed at higher risk of thyroid problems during pregnancy) and recommendations on the use of thyroid reference ranges during pregnancy to reduce the diagnosis of mild disease and increase the relative number of cases of overt hypothyroidism and hypothyroxinemia identified [Korevaar TIM, Nov 2024. MedEA Thyroid Disorders Webinar Presentation]. ATA Guidelines are also due on the treatment of thyroid cancer and on nodule management, with updates on the need for levothyroxine replacement after lobectomy, and TSH targets for levothyroxine-treated thyroidectomized thyroid cancer patients. This learning journey has been planned with these new guidelines as central to the activities, helping to highlight and disseminate changes to best practice and further enhance patient care.  Other educational needs identified during the development of this programme consolidate the need for personalization of therapy, attending to consistent signals from subpopulations that may enhance current thinking. Themes that will be explored during the learning journey include the role of T3, especially in those treated with LT4 [Ettleson, 2020; Wiersinga, 2019], the role of the gut thyroid axis and the gut microbiome [Jiang, 2022; Stramazzo, 2023; Knezevic, 2020], and how each of these may impact patient physical and mental health and ultimately, quality of life. These topics are not viewed in isolation, but are interconnected with a degree of commonality that will be explored during the activities. The overwhelming message from this learning journey is that medicine for thyroid disorders needs to be holistic and personalized to provide optimum care.